Reactivation of CNV after discontinuation of bevacizumab treatment of age-related macular degeneration

Conclusion: Based on quiescent disease, anti-VEGF therapy was discontinued in 58% of patients after they received bevacizumab injections every 4, 6, or 8 weeks for one year; 67% sh owed reactivated CNV within the year after discontinuation. The high reactivation rate of CNV shown in this study, should help clinicians develop rational discontinuation protocols.
Source: Ophthalmologica - Category: Opthalmology Source Type: research